- Home
- A-Z Publications
- Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents)
- Previous Issues
- Volume 4, Issue 1, 2006
Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents) - Volume 4, Issue 1, 2006
Volume 4, Issue 1, 2006
-
-
Cardiotoxicity of 5-Fluorouracil
Authors: P. Alter, M. Herzum, M. Soufi, J. R. Schaefer and B. MaischCardiac side effects of the cytostatic agent 5-fluorouracil (5-FU) have an incidence of 1.2 - 7.6%. Potentially, arrhythmias, myocardial infarction and sudden cardiac death could occur. Life-threatening cardiotoxicity is rarely observed with a frequency <1%. Cardiotoxicity of 5-FU seems to differ from well known effects of other cytostatics, e.g., anthracyclines. Myocardial ischemia was suggested as potential mechanism due to oc Read More
-
-
-
Pharmacogenomics of Essential Hypertension: Are We Going the Right Way?
Authors: F. Filigheddu, C. Troffa and N. GloriosoIdentifying the genetic predictors of the therapeutic response to drugs is the role of pharmacogenomics. Although polymorphisms in several genes have been associated with the blood pressure response to diuretics, β-blockers and ACE-inhibitors, the pharmacogenomics of essential hypertension is still attempting to find satisfactory scientific evidence to be translated into clinical practice. The main reasons for this ap Read More
-
-
-
Imidazoline Receptors, Novel Agents and Therapeutic Potential
Authors: G. A. Head and D. N. MayorovThe initial realization that agents containing an imidazoline structure may interact with a distinct class of receptors, has led to a major class of cardiovascular agents, which now has the potential to enter a third generation. There is now general acceptance that there are three main imidazoline receptor classes, the I1 imidazoline receptor which mediates the sympatho-inhibitory actions to lower blood pressure, the I2 Read More
-
-
-
Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects
Authors: G. Leone, S. Sica, M. T. Voso, S. Rutella and L. PaganoMonoclonal antibodies are a new class of agents targeted at specific receptors on cancer cells. In addition to direct cellular effects, antibodies can carry substances to the targeted cells, such as radioactive isotopes, toxins, and antineoplastic agents. At present monoclonal antibodies, directed against both lymphoid antigens (CD 20 and CD 52) and a myeloid antigen (CD33) are available for clinical use. In ALL, rituximab, a huma Read More
-
-
-
Pathophysiological Basis for Anticoagulant and Antithrombotic Therapy in Pulmonary Hypertension
More LessIn pulmonary hypertension (PH), thrombosis and thromboembolism may occur as primary events associated with inherited or acquired thrombophilia. Alternatively, in situ thrombosis may develop as a complication of pre-existing vasculopathy as in the case of idiopathic PH and related disorders (so called pulmonary arterial hypertension). In these disorders, a number of abnormalities has been described involvin Read More
-
-
-
A New Antihypertensive Agent that Antagonizes the Prohypertensive Effect of Endogenous Ouabain and Adducin
Authors: Paolo Manunta, Mara Ferrandi, Elisabetta Messaggio and Patrizia FerrariEndogenous Ouabain (EO) and Adducin enhance the Na-K pump function and play an important role in sodium homeostasis and blood pressure (BP) regulation. In the general population, plasma EO modulates BP either by inhibiting the prohypertensive effect of an excessive salt intake or counteracting the depressor action of normal-moderate salt intake. Almost 50% of hypertensive patients have increased circulating plas Read More
-
-
-
Angiotensin Receptor Blockers in Hypertension and Cardiovascular Diseases
More LessAngiotensin receptor blockers are the newest class of antihypertensive agents marketed for the treatment of hypertension. There is now an important amount of evidence indicating that this class of drugs exerts beneficial effects in patients with a variety of cardiovascular disorders. Evidence-based medicine includes well controlled studies with mortality and morbidity endpoints in patients with left ventricular dysfunct Read More
-
-
-
Mineralocorticoid Receptor Blockade in the Protection of Target Organ Damage
Authors: Paolo Mulatero, Alberto Milan, Tracy A. Williams and Franco VeglioOver the last decade a wealth of studies have shed new light on the role of aldosterone in the pathogenesis of cardiovascular diseases. It is now evident that in addition to its classical role in increasing sodium reabsorbtion in the kidney , aldosterone also exhibits several nonepithelial effects such as the induction of inflammation, fibrosis and necrosis in various organs. Herein we review the experimental evidences for the prot Read More
-
Volumes & issues
-
Volume 23 (2025)
-
Volume 22 (2024)
-
Volume 21 (2023)
-
Volume 20 (2022)
-
Volume 19 (2021)
-
Volume 18 (2020)
-
Volume 2 (2020)
-
Volume 17 (2019)
-
Volume 16 (2018)
-
Volume 15 (2017)
-
Volume 14 (2016)
-
Volume 13 (2015)
-
Volume 12 (2014)
-
Volume 11 (2013)
-
Volume 10 (2012)
-
Volume 9 (2011)
-
Volume 8 (2010)
-
Volume 7 (2009)
-
Volume 6 (2008)
-
Volume 5 (2007)
-
Volume 4 (2006)
Most Read This Month
Article
content/journals/chamc
Journal
10
5
false
en
